Brentuximab Vedotin for Systemic Sclerosis

(

BRAVOS

)

ITN Protocol #:

ITN075AI

Branded Name:

BRAVOS

ClinicalTrials.Gov ID:

NCT03222492

Treatment Protocol #:

Therapeutic Area:

Autoimmune Disease

Current Status:

Analysis

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Study Personnel:

Protocol Chair

David Fox, MD dfox@umich.edu

Work:

734-936-5566

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Karen Chia kchia@immunetolerance.org

Work:

415-353-4290

Protocol Chair

Laura Cooney, PhD lcooney@immunetolerance.org

Work:

734-274-1149

Protocol Chair

Dawn Smilek, MD PhD dsmilek@immunetolerance.org

Work:

415-353-4308

Protocol Chair

Beverly Welch BWelch@niaid.nih.gov

Work:

(202) 476-5278

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379